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Abstract: We report the construction of conjugates between 
several variants of the helix 3 region of a Q50K engrailed 
homeodomain and bisbenzamidine minor groove DNA binders. 
While the hybrid featuring the sequence of the native protein fails 
to bind to DNA, designed modifications that increase the alpha-
helical folding propensity of the peptide allowed specific DNA 
binding through a bipartite major-minor groove interaction.  
Transcription Factors (TFs) are specialized proteins that 
regulate gene expression. These proteins recognize specific 
DNA sequences through specialized DNA-binding domains,[1] 
and upon binding to these sites they promote -or inhibit- the 
process of transcription.[2] As a result of this key role in the 
regulation of gene expression, it is not surprising that 
alterations in the activity of TFs are at the origin of many 
diseases, including cancer.[3] In this context, the development 
of non-natural agents that can mimic the dsDNA recognition 
properties of TFs, and potentially lead to new gene targeting 
tools, remains a major goal in biological chemistry.[ 4 ] TFs 
establish specific interactions with their DNA target sequences 
through relatively few residues located in their recognition 
motifs, in many cases alpha helices inserted in the DNA major 
groove. However, these motifs, when isolated from the rest of 
the protein, fail to show any significant DNA binding ability,[5] 
and therefore the preparation of small peptide models of DNA-
binding proteins is a highly challenging task.[6] In recent years 
we have shown that the DNA binding ability of some of these 
regions can be recovered when appropriate tethered to minor 
groove binders like distamycin or propamidine, so that the 
resulting conjugates bind designed composite sites through a 
bivalent interaction.[ 7 ] This DNA binding strategy has been 
successfully applied in the case of the basic regions of bZIP 
proteins like GCN4,[7] as well as for the zinc finger module of 
GAGA.[8] 
Homedomain proteins (HD) are highly conserved 
transcription factors that play key roles in eukaryotic 
development and work by interacting to DNA through a 
bipartite structure consisting of a helix-turn-helix motif and a 
minor groove binding N-terminal arm.[9] The major groove DNA 
contacts are mainly accomplished by the helix 3 of the protein 
(h3), which, as expected, when isolated from the rest of the 
protein fails to fold into an alpha-helix structure and bind to its 
cognate DNA.[10] Considering our previous designs with other 
DNA binding proteins, we wondered whether tethering of this 
h3 region of a homedomain to a minor groove binder might 
suffice for recovering a reasonable DNA interaction. In addition 
of the intrinsic interest of answering this question, the resulting 
conjugates are quite appealing as they might be considered as 
artificial mimics of natural homedomains because of the 
bipartite minor-major groove interaction.  
As shown below, hybrids between a bisbenzamidine and a 
short DNA recognition region of the engrailed homeodomain 
fail to bind DNA. However, we demonstrate that a rational 
grafting of the peptide moiety allows for the recovery of specific 
binding to the designed DNA site.  
The strategy was investigated using the Q50K engrailed 
homeodomain (En-HD), an archetypical member of this family 
that binds with good affinity to the QRE site (GGATTA).[ 11 ] 
Preliminary molecular modeling studies based on the crystal 
structure of En-HD bound to its target DNA,[12] suggested that a 
peptide consisting of residues Asn41 to Ser59 of the helix 3 of 
the protein could be used as reference for building our hybrids. 
Therefore we made the conjugate En-HDh3-1 in which the 
Gln44 was mutated to a lysine to allow the connection of the 
minor groove binder. We have previously shown that 
bisbenzamidines are readily available minor groove binders 
that show micromolar affinities for A/T-rich segments of 
DNA,[13] and can be easily modified to introduce the linkers 
required for conjugation to the peptide.[14] 
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Figure 1. Left: Representation of an En-HD/DNA complex. Right: 
Hypothetical model of a DNA complex with a bisbenzamidine/En-DHh 
conjugate. Bottom: Peptide sequence of the Q44K engrailed helix 3 (En-HD) 
and of the conjugates synthesized in this article [Lys44, which is used to 
attach the minor groove binder to the peptide (darker cylinder) is highlighted].  
 Detailed procedures for the synthesis of the hybrid En-
HDh3-1 are given in the experimental section. In short, the 
peptide scaffolds were assembled following standard Fmoc/tBu 
solid phase peptide synthesis protocols.[15] The Lys44 residue 
was introduced in the sequences with its side chain protected 
as an alloc carbamate, which could be orthogonally removed 
with Pd catalysis while the peptides were still attached to the 
solid support.[ 16 ] A subsequent derivatization with glutaric 
anhydride allowed to increase the length of the linker while 
simultaneously installing a carboxylic acid for attaching the 
bisbenzamidine amine derivative bb1 (see the Supporting 
Information). Coupling of the required amino-bisbenzamidine to 
the peptide was performed by activating the glutaric 
carboxylate with HATU (Scheme 1). The final conjugate was 
deprotected and liberated from the solid support by treatment 
with TFA, and purified using reverse-phase HPLC.  
 
 
Scheme 1. Key steps in the synthesis of the conjugate En-HDh3-1 based on 
Q50K (Asn41-Ser59, the key Lys44 required for derivatization is indicated). 
The interaction of En-HDh3-1 with the DNA was studied by 
electrophoretic mobility shift assays (EMSA) under non-
denaturing conditions in polyacrylamide gels,[ 17 ] and using 
double stranded oligonucleotides containing the target 
composite DNA binding site GGATTAAA (QRE-A/T). 
Unfortunately, the gels did not show the expected retarded 
bands indicating the formation of stable En-HDh3-1/DNA 
complexes  (Figure 2A). In consonance with this failing, circular 
dichroism (CD) spectroscopy revealed that the addition of the 
cognate DNA to the conjugate does not promote a significant 
alpha helical folding (Figure 2B). Therefore, despite the 
presence of the bisbenzamidine and the relatively basic 
peptide region of En-HDh3, we do not observe a significant 
DNA interaction. We also made a related conjugate featuring a 
longer connector between the peptide and the bisbenzamidine, 
but it also failed to give relevant interactions (En-HDh3-1b, see 
the Supporting Information). 
 The recognition helix of HD proteins is usually shorter 
and makes fewer contacts with the DNA than those present in 
other TFs, such as in the bZIP family, and this might be one of 
the reasons behind the failing of our derivatives to interact to 
DNA. The presence of the rest of the homeodomain protein 
(helix 1 and 2) is critical for promoting the required α-helix 
folding of h3.  
 
Figure 2. A) EMSA results showing the absence of retarded bands upon 
mixing conjugate En-HDh3-1 and QRE-A/T. Lanes 1-4: [HDh3-1] = 0, 500, 
800 and 1000 nM. Experiment was resolved by PAGE on a 10% 
nondenaturing polyacrylamide gel and 0.5xTBE buffer over 40 min at RT 
and analyzed by staining with SyBrGold (Molecular Probes: 5 μL in 50 mL 
of 1xTBE) for 10 min, followed by fluorescence visualization. B) Circular 
dichroism spectra of a 5 μM solution of HDh3-1 (black solid line); in the 
presence of 1 equiv of QRE-A/T (solid line); same solution in the presence 
of 5 μM MUT-A/T DNA (dashed line). The CD spectra of the peptides (when 
measured in the presence of DNA) were calculated as the difference 
between the spectrum of the peptide/DNA mixture and the measured 
spectrum of a sample of the DNA oligonucleotide sequences (binding sites 
in italics, only one strand shown): QRE-A/T: 5'-CGTGC GGATTAAA 
AGCTGCG-3'; MUT-A/T: 5'-CGTGC GACTTAAA AGCTGCG-3'. 
 To compensate for the loss of the nucleating effect 
provided by the full HD structure, we considered the design of 
a modified helix based on the bZIP transcription factor GCN4. 
The idea consisted on grafting key DNA contacting amino 
acids of En-HD into the basic region of GCN4. We therefore 
constructed the conjugate En-HDh3-2, in which the peptide is 
a combination of the h3 of engrailed and the amino acids 226-
248 of GCN4.[18] We also designed a second peptidic domain 
in which the residues not involved in DNA binding were 
replaced by alanines,[ 19 ] while keeping the short N-terminal 
capping motif of GCN4 (DPAAL, hybrid En-HDh3-3). In both 
cases the tether between the bisbenzamidine and the peptide 
includes a secondary amine in the linker, which could favor the 
phosphate backbone crossover.[ 20 ] The synthesis of the 
conjugates was achieved using a strategy similar to that 
previously described, but with the required 
aminobisbenzamidine partner for the coupling reaction (bb2, 
Scheme 2, and Supporting Information).  
 
          
 
Scheme 2. Key steps in the synthesis of the conjugates En-HDh3-2 and En-
HDh3-3 based on engrailed homeodomain (only the key Lys44 required for 
the coupling is indicated). En-HDh3-2 and EnHDh3-3 differ only in the 
peptide sequence (see Figure 1 and Supporting Information for details). 
Interestingly, and in contrast to the failing of the previous 
constructs, EMSA experiments with conjugates En-HDh3-2 
and En-HDh3-3 and the ds-oligonucleotide QRE-A/T showed 
the presence of a new slower-migrating band (band b), 
consistent with the formation of specific complexes between 
the peptide conjugates and the dsDNA (Figure 3A and 3B, top 
panels). Isothermal titrations allowed to calculate a KD of ≈ 188 
nM at 4 ºC for En-HDh3-2 and a KD of ≈ 131 nM for En-HDh3-3, 
which denotes a quite reasonable interaction. Importantly, 
incubation of the hybrids with an oligonucleotide containing a 
double mutation in its peptide-binding site (MUT-A/T) does not 
elicit stable complexes (Figure 3A and 3B, bottom panels), 
which confirms a highly selective interaction with the target 
DNA.[21]  
 
Figure 3. A) EMSA results for conjugate En-HDh3-2. Lanes 1-3: [En-HDh3-
2] = 0, 200, 500 nM with 50 nM of QRE-A/T dsDNA. Lanes 4-6: [En-HDh3-2] 
= 0, 750, 1000 with 50 nM of MUT-A/T dsDNA B) EMSA results for conjugate 
En-HDh3-3. Lanes 1-3: [En-HDh3-3] = 0, 200, 500 nM with 50 nM of QRE-
A/T dsDNA. Lanes 4-6: [En-HDh3-3] = 0, 750, 1000 with 50 nM of MUT-A/T 
dsDNA. C) Circular dichroism spectra of a 5 μM solution of En-HDh3-2 (thick 
solid line) in the presence of 1 eq. of QRE-A/T dsDNA (solid line), and in the 
presence of 5 μM MUT-A/T dsDNA (dashed line). D) Same experiment for 
conjugate En-HDh3-3. Oligonucleotide sequences (binding sites in italics, 
only one strand shown): QRE-A/T: 5'-CGTGC GGATTAAA AGCTGCG-3'; 
MUT-A/T: 5'-CGTGC GACTTAAA AGCT GCG-3'. 
The increased affinity of En-HDh3-3 is consistent with its 
higher content in Ala residues, and therefore a greater 
tendency for alpha-helix folding.[ 22 ] Circular dichroism 
experiments showed that upon addition of the double stranded 
oligonucleotide containing the target sequence (QRE-A/T), 
both peptides experiment a significant increase in helical 
content, particularly for En-HDh3-3, which is consistent with 
the higher binding affinity found by EMSA. Curiously, while the 
addition of the mutated DNA to En-HDh3-2 does not promote 
α-helical folding, addition to En-HDh3-3 led to a notable 
increase in the negative intensity of the band at 222 nm. This 
can be interpreted in terms of the higher intrinsic α-helical 
propensity of the Ala-equipped peptide that favors its partial 
folding even in the presence of non-specific DNA.[23] On the 
other hand, the positive CD band centered at 330 nm, which is 
more intense for the better binder En-HDh3-3, must arise from 
insertion of the bisbenzamidine unit into the DNA minor 
groove.[24] 
In summary, we have shown that by combining an 
appropriate amino acid grafting with the tethering of a minor 
groove binder, h3 regions of homedomain proteins can be 
induced to bind specific DNA sites with good affinity and very 
good selectivity. The resulting conjugates simulate the DNA 
recognition of native homedomains by binding to similar 
sequences by a bipartite major and minor group interaction. 
This type of constructs might open unique opportunities for 
interfering with the activity of homedomain transcription factors, 
and therefore for altering gene processes related to eukaryotic 
development.  
Experimental Section 
Electrophoretic Mobility Shift Assay. EMSA was performed 
with a BioRad Mini Protean gel system, powered by an 
electrophoresis power supplies PowerPac Basic model, 
maximum power 150 V, frequency 50.60 Hz at 140 V (constant 
V). Gel mobility shift assays binding reactions were performed 
over 50 min. in 18 mM Tris (pH 7.0), 50 mM KCl, 1.2 mM MgCl2, 
0.5 mM EDTA, 9% glycerol, 0.11 mg/mL BSA and 4.2% NP−40 
at 4 ºC. In the experiments analyzed by fluorescent staining we 
used 50 nM of the unlabeled dsDNAs and a total incubation 
volume of 20 µL. Products were resolved by PAGE using a 
10% non-denaturing poliacrylamide gel and 0.5X TBE buffer, 
and analyzed by staining with SyBrGold (Molecular Probes: 5 
µL in 50 mL of 1X TBE) for 10 min and visualized by 
fluorescence. 
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Circular Dichroism spectroscopy. CD measurements were 
made in a 2 mm cell at 4 ºC. Samples contained 5 µM of 
corresponding dsDNA (when present) and 5 µM of peptides in 
10 mM phosphate buffer (pH 7.5) and 100 mM of NaCl. The CD 
spectra of the peptides (when measured in the presence of 
DNA) were calculated as the difference between the spectrum 
of the peptide/DNA mixture and the measured spectrum of a 
sample of the DNA oligonucleotide.  
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